-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite reports prolonged disease control in Phase 2a namodenoson pancreatic cancer trial

PUBT·06/02/2026 11:03:38
Listen to the news
Can-Fite reports prolonged disease control in Phase 2a namodenoson pancreatic cancer trial
  • Can-Fite highlighted encouraging clinical observations from its Phase 2a trial of namodenoson monotherapy in pancreatic cancer.
  • Enrollment has been completed. Results have not been presented. The update referenced research discussed around the 2026 ASCO meeting.
  • Several patients showed prolonged disease control, including one who has stayed on treatment and follow-up for about 16 months.
  • The company also emphasized a differentiated mechanism that includes RAS pathway inhibition, supporting a potential positioning in KRAS-driven pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020700PRIMZONEFULLFEED9730420) on June 02, 2026, and is solely responsible for the information contained therein.